FDA And ESA Safety: A Conversation With Bob Temple And Ellis Unger
Executive Summary
The January 6 issue of the New England Journal of Medicine featured another editorial in a continuing series of major FDA communications on regulatory policy. In this case, the subject of the agency's evaluations was the safety of erythropoiesis-stimulating agents (ESAs)
You may also be interested in...
Changing Of The Guard At US FDA Continues With Unger Retirement
One of the US FDA’s most prominent review managers is retiring after nearly 25 years with the agency. Ellis Unger’s departure underscores a sense of transition in the leadership and mindset of the drug center.
Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars
FDA is ending one of the landmark drug safety programs from the REMS era, announcing it has released Amgen from its mandatory obligations for the erythropoiesis-stimulating agent (ESA) class. The decision comes just ahead of the likely approval of the first biosimilar application in the class.
Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars
FDA is ending one of the landmark drug safety programs from the REMS era, announcing it has released Amgen from its mandatory obligations for the erythropoiesis-stimulating agent (ESA) class. The decision comes just ahead of the likely approval of the first biosimilar application in the class.